FDA OKs Vitatron's pacemaker software upgrade:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Vitatron's Ventricular Rate Stabilization (VRS) software upgrade for patients implanted with the company's Selection AFm pacemaker system. VRS can help stabilise the rate of the heart's ventricles during episodes of conducted atrial fibrillation (AF), which may reduce the symptoms of AF. It can be uploaded into the pacemaker - without the need for surgery - simply by placing a programming device on the chest over the patient's pacemaker, says Vitatron, a unit of Medtronic.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.